Cord Blood America Says Referral Program a Success: 21 Percent of Total Sales

Oct 31, 2011, 05:02 ET from Cord Blood America, Inc.

LAS VEGAS, Oct. 31, 2011 /PRNewswire/ -- Cord Blood America, Inc. ( (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that since it launched a Referral Rewards Program on July 7, 2011, referral sales have risen from 8 to 21 percent of total sales.

The program, announced by CorCell, its domestic brand for cord blood stem cell collection and storage, offers $200 to anyone making a referral and a $200 discount on the enrollment fee for the family.

"We believed this program would be a success, and that friends would tell friends about the importance of saving a baby's stem cells at the time of birth, but even we didn't envision the program succeeding this well," said Erin Tecca, Business Development Manager.  "Quarter over quarter, the new enrollee sales are increasing by five percent."

"We always have had a great number of referrals, most from within our customer base, but with the new Referral Rewards Program we are receiving referrals from a much larger network of people," Ms. Tecca said. 

Cord blood stem cells are used today to treat 75 diseases including leukemia, severe anemia, metabolic blood disorders and immune deficiencies, with ongoing research worldwide to treat many of the world's most serious diseases, including diabetes, heart disease and stroke.

About Cord Blood America

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at For investor information, visit


Paul Knopick E & E Communications 949/707-5365

SOURCE Cord Blood America, Inc.